Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.

Autor: Muralidharan S; SOTIO Biotech Inc., Cambridge, MA 02140, USA.; These authors contributed equally to this work., Kervarrec T; Department of Dermatology, University Hospital of Tours, Tours 37170, France.; These authors contributed equally to this work., Weiss GJ; SOTIO Biotech Inc., Cambridge, MA 02140, USA., Samimi M; Department of Dermatology, University Hospital of Tours, Tours 37170, France.

Publikováno v: Oncotarget [Oncotarget] 2022 Aug 03; Vol. 13, pp. 960-967. Date of Electronic Publication: 2022 Aug 03 (Print Publication: 2022).

Imaging Ligands Targeting Glypican-3 (GPC3) Receptor Expression in Hepatocellular Carcinoma

Autor: Shaun D. Grega, David Z. Zheng, Qi-Huang Zheng

Publikováno v: Proceedings of IMPRS. 5

Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality and is increasing in incidence worldwide. Early detection of HCC is important since potentially curative therapies exist in the initial stages of HCC; no curative therapies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b46b58634f2c8bf108f1c83d51d697a5
https://doi.org/10.18060/26670

Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells

Autor: Sakurai, Maiko, Shibata, Kiyosumi, Umezu, Tomokazu, Kajiyama, Hiroaki, Yamamoto, Eiko, Ino, Kazuhiko, Nawa, Akihiro, Kikkawa, Fumitaka

Publikováno v: In Gynecologic Oncology 2010 119(2):332-336

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.